BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19382596)

  • 1. [Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
    Garajová I; Svoboda M; Slabý O; Kocáková I; Fabian P; Kocák I; Vyzula R
    Klin Onkol; 2008; 21(6):330-7. PubMed ID: 19382596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
    Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
    Lay GC; Caraul B; Dessì M; Orrù S; Murtas R; Deidda MA; Farigu R; Farci D; Maxia L; Casula G; Amichetti M
    J Exp Clin Cancer Res; 2007 Mar; 26(1):61-70. PubMed ID: 17550133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
    Balboa E; Duran G; Lamas MJ; Gomez-Caamaño A; Celeiro-Muñoz C; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2010 Jun; 11(6):747-61. PubMed ID: 20504250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
    Soumarova R; Skrovina M; Bartos J; Gruna J; Wendrinski A; Czudek S; Kycina R; Parvez J
    Eur J Surg Oncol; 2010 Mar; 36(3):251-6. PubMed ID: 19879716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
    Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC
    Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
    Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
    Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Velenik V; Anderluh F; Oblak I; Strojan P; Zakotnik B
    Croat Med J; 2006 Oct; 47(5):693-700. PubMed ID: 17042060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
    Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
    Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
    Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
    Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gene expression profiling in prediction of tumor response to neoadjuvant concomitant chemoradiotherapy in patients with locally advanced rectal carcinoma: pilot study].
    Garajová I; Slabý O; Svoboda M; Fabian P; Silák J; Smerdová T; Kocák I; Růzicková J; Hoch J; Vyzula R
    Cas Lek Cesk; 2008; 147(7):381-6. PubMed ID: 18678097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study.
    Caravatta L; Padula GD; Picardi V; Macchia G; Deodato F; Massaccesi M; Sofo L; Pacelli F; Rotondi F; Cecere G; Sallustio G; Di Lullo L; Piscopo A; Mignogna S; Bonomo P; Cellini N; Valentini V; Morganti AG
    Acta Oncol; 2011 Nov; 50(8):1151-7. PubMed ID: 21851185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
    Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer.
    Ben-Josef E
    Am J Clin Oncol; 2007 Dec; 30(6):649-55. PubMed ID: 18091061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
    Vestermark LW; Jacobsen A; Qvortrup C; Hansen F; Bisgaard C; Baatrup G; Rasmussen P; Pfeiffer P
    Acta Oncol; 2008; 47(3):428-33. PubMed ID: 18348002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
    Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
    J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
    Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
    J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
    Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
    J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rectal cancer adjuvant chemotherapy: when is more useful?
    Pasetto LM; Basso U; Sinigaglia G; Pucciarelli S; Friso ML; Rugge M; Toppan P; Agostini M; Monfardini S
    Anticancer Res; 2008; 28(3B):1805-12. PubMed ID: 18630464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.